Trials / Completed
CompletedNCT01323530
A Confirmation Study of Eribulin in Combination With Capecitabine
A Phase 1b/2, Multicenter, Open-Label, Dose-Escalation and Confirmation Study of Eribulin in Combination With Capecitabine
- Status
- Completed
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 76 (actual)
- Sponsor
- Eisai Limited · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a Phase 1b/2, multi-center, open-label, dose escalation (in 2 different dosing schedules \[1 and 2\]) and dose-confirmation study of eribulin administered in combination with capecitabine.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Eribulin mesylate | Intravenous (IV) bolus or infusion. |
| DRUG | Capecitabine | Oral film-coated tablets. |
Timeline
- Start date
- 2010-01-26
- Primary completion
- 2014-07-28
- Completion
- 2015-10-13
- First posted
- 2011-03-25
- Last updated
- 2021-01-11
- Results posted
- 2021-01-11
Locations
10 sites across 3 countries: Bulgaria, Russia, United Kingdom
Source: ClinicalTrials.gov record NCT01323530. Inclusion in this directory is not an endorsement.